Ipamorelin, the first selective growth hormone secretagogue

European Journal of Endocrinology

Volumn 139, Issue 5, 1998, Pages 552-561

  Raun, Kirsten ^a   Hansen, Birgit Sehested ^a   Johansen, Nils Langeland ^a   Thøgersen, Henning ^a   Madsen, Kjeld ^a   Ankersen, Michael ^a   Andersen, Peter Høngaard ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; IPAMORELIN; LUTEINIZING HORMONE; PROLACTIN; THYROTROPIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031792717     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1390552     Document Type: Article

References (38)

1. Clemmesen B, Overgaard K, Riis B & Christiansen C. Human growth-hormone and growth-hormone releasing hormone - a double-masked, placebo-controlled study of their effects on bone metabolism in elderly women. Osteoporosis International 1993 3 330-336.
2. Vara-Thorbeck R, Guerrero JA, Rosel J, Ruiz-Requena E & Capitán JM. Exogenous growth hormone: effects on the catabolic response to surgically produced acute stress and on postoperative immune function. World Journal of Surgery 1993 17 530-538.
3. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L & Bengtsson B. Growth-hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. Journal of Clinical Endocrinology and Metabolism 1997 82 727-734.
4. Fukata J, Diamond D & Martin JB. Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells. Endocrinology 1985 117 457-467.
5. Argente J & Chowen JA. Neuroendocrinology of growth hormone secretion. Growth Genetics and Hormones 1994 10 1-5.
6. Bowers CY, Momany F, Reynolds GA, Hong A & Newlander K. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984 114 1537-1545.
7. Chowen JA, Nowak J, Eschen C, González-Para S, Garciía-Segura LM & Argente J. Growth hormone releasing peptide-6 (GHRP-6) modulates specific populations of growth hormone releasing hormone (GHRH) and somatostatin (SS) neurons in dwarf rats. Hormone Research 1995 44 A74.
8. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat, KJ, Johnston DBR, Cheng K, Chan WWS, Butler B, Hickey G, Jacks T, Schleim K, Pong SS, Chaung LYP, Chen HY, Frazier E, Leung KH, Chiu SHL & Smith RG. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the USA 1995 92 7001-7005.
9. Bowers CY. On a peptidomimetic growth hormone-releasing peptide. Journal of Clinical Endocrinology and Metabolism 1994 79 940-942.
10. Cheng K, Chan WW-S, Butler B, Wei L, Schoen WR, Wyvratt Jr M, Fischer M & Smith RG. Mechanism of action of L-692,429, a novel non-peptidyl GH secretagogue on rat growth hormone release both in vitro and in vivo. 75th Annual Meeting of The Endocrine Society, Las Vegas, Nevada 1993, p 297 (Abstract).
11. Hickey GJ, Jacks T, Judith F, Taylor J, Schoen WR, Krupa D, Cunningham P, Clark J & Smith R. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. Endocrinology 1994 134 695-701.
12. Hickey G, Drisko J, Faidley T, Chang C, Anderson LL, Nicolich S, Mcguire L, Rickes E, Krupa D, Feeney W, Friscino B, Cunningham P, Frazier E, Chen HY, Laroque P & Smith RG. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. Journal of Endocrinology 1996 148 371-380.
13. Tiulpakov AN, Brook CG, Pringle PJ, Peterkova VA, Volevodz NN & Bowers CY. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clinical Endocrinology 1995 3 347-350.
14. Bowers CY. GH releasing peptides - structure and kinetics. Journal of Pediatric Endocrinology 1993 6 21-31.
15. Chigo E, Awat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R & Camanni F. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology and Metabolism 1994 78 693-698.
16. Copinschi G, Vanonderbergen A, Lhermitebaleriaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, Desmet M, Thorner MO & Vancauter E. Effects of a 7-day treatment with a novel, orally-active, growth-hormone (GH) secretagogue, MK-677, on 24-h GH profiles, insulin-like growth-factor-I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism 1996 81 2776-2782.
17. Arvat E, Divito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F & Ghigo E. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man - comparison with the effects of GHRH, TRH and HCRH. Peptides 1997 18 885-891.
18. Clark RG, Thomas GB, Mortensen DL, Won WB, Ma YH, Tomlinson EE, Fairhall KM & Robinson ICAF. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the zucker diabetic fatty rat. Endocrinology 1997 138 4316-4323.
19. Heiman ML, Nekola MV, Murphy WA, Lance VA & Coy DH. An extremely sensitive in vitro model for elucidating structure-activity relationships of growth hormone releasing factor analogs. Endocrinology 1985 116 410-415.
20. Janssens CJJG, Helmond LWS, Loyens WGP, Schouten WGP & Wiegant VM. Chronic stress increases the opioid-mediated inhibition of the pituitary-adrenocortical response to acute stress in swine. Endocrinology 1995 136 1468-1473.
21. Van der Meulen J, Helmond FA, Oudenaarden CPJ, Van der Lende T & Te Kronnie G. Effect of injection of a GnRH analogue at the onset of oestrus on LH and FSH release and embryonic mortality in gilts. Netherland Journal of Agricultural Science 1993 4 37-43.
22. Van Landeghem AAJ & Van de Wiel DFM. Radioimmunoassay for porcine prolactin. Plasma levels during lactation, suckling and weaning, and TRH administration. Acta Endocrinologica 1978 88 653-659.
23. Janssens CJJG, Helmond FA & Wiegant VM. Increased cortisol response to exogenous adrenocorticotropic hormone in chronically stressed swine: influence of housing conditions. Journal of Animal Science 1994 72 1771-1777.
24. 50) of an enzymatic reaction. Biochemical Pharmacology 1973 22 3099-3108.
25. Ankersen M & Hansen BS. Novel simple thioureas with growth hormone releasing properties. European Journal of Medicinal Chemistry 1997 32 631-635.
26. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 1989 124 2791-2798.
27. Cheng K, Chan WW, Butler B, Wei L & Smith RG. A novel non-peptidyl growth hormone secretagogue. Hormone Research 1993 40 109-115.
28. Robberecht P, Coy DH, Waelbroeck M, Heiman ML, de Neef P, Camus JC & Christophe J. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): Endocrinology 1985 117 1759-1764.
29. Bustad LK, Mclellan RO & Burns MP. Swine in biomedical research. Proceedings of a Symposium at the Pacific Northwest Laboratory, Richland, Washington, Batelle Memorial Institute, 1966 (abstract).
30. Claus R, Bingel A, Hofäcker S & Weiler U. Twenty-four hour profiles of growth hormone (GH) concentrations in mature female and entire male domestic swine in comparison with mature wild boars (Sus scrofa L.). Livestock Production Science 1990 25 247-255.
31. Raun K. The effect of repeated GHRP-6 i.v. injections in swine. Serono Meeting, St Petersborg, Florida, USA 1994 (abstract).
32. Chang CH, Rickes EL, Marsilio F, McGurie L, Cosgrove S, Taylor J, Chen H, Feighner S, Clark JN, De Vita R, Schoen W, Wyratt M, Fisher Jr M, Smith RG & Hickey GJ. Activity of a novel nonpeptidyl growth hormone secretagogue, L-700,653, in swine. Endocrinology 1995 136 1065-1071.
33. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D, Feeney W, Schoen W, Ok D, Fisher M, Wyvratt M & Smith R. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. Endocrinology 1994 143 399-406.
34. Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C & Casanueva F. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clinical Endocrinology 1994 41 649-654.
35. Casati G, Palmieri E, Biella O, Guglielmino L, Arosio M & Faglia G. Effects of hexarelin (EP 23905-MF 6003) on circulating GH, PRL, TSH, gonadotropins and a-subunit of glycoprotein hormone levels in acromegalic patients. European Journal of Endocrinology 1994 130 (Suppl 2) P3.004 (Abstract).
36. Pasolli HA, Torres AI & Aoki A. The mammosomatotroph - a transitional cell between growth hormone and prolactin producing cells: an immunocytochemical study. Histochemistry 1994 102 287-296.
37. Shinkai T, Sakurai Y & Ooka H. Age-related changes in the numbers of mammotrophs, somatotrophs and mammosomatotrophs in the anterior pituitary gland of female rats - a flow cytometric study. Mechanisms of Ageing and Development 1995 83 125-131.
38. Van der Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P & Bouillons R Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Clinical Endocrinology 1996 45 341-351.